O-1A Case Study: Visa Approval for Oncology Researcher from Russia Russian Federation Oncology ResearcherColombo & Hurd secured O-1A approval for an oncology researcher from Russia focused on developing colorectal cancer therapies. USCIS approved the petition without issuing a Request for Evidence (RFE). Developing new cancer treatments takes years of specialized work. Research organizations run clinical trials across many countries to test new therapies, and they depend on senior medical professionals to keep patients safe and the science sound. The doctors who lead this work help decide whether a new treatment ever reaches patients. Our client has spent much of his career in that role, overseeing patient safety, reviewing trial results, and guiding the development of cancer therapies tested across multiple countries. Senior Immigration Attorney Rachel Slomski led the O-1A petition. Evaluate My Profile Client ProfileFrom Treating Cancer to Developing New Treatments O-1 VisasOur client is a physician with more than 25 years of experience in oncology. He earned his Medical Degree and a PhD in medicine, and he has spent his career studying and treating cancer. Much of his work focuses on colorectal cancer, which is one of the most common cancers worldwide. Early in his career, he helped develop a new way to treat patients with advanced-stage cancer who arrived at the hospital with serious complications. Doctors had long considered these patients too sick for surgery and offered them only comfort care. His approach combined surgery with additional therapy, and it helped these patients live longer. He published this research and other doctors began using it in their own hospitals. As his career progressed, he moved from treating patients to guiding the development of new cancer drugs. He has worked with research organizations that run clinical trials in more than twelve countries, helping test new therapies for cancer. In these roles, he oversees patient safety and reviews trial results. Several of the treatments he worked on have gone on to receive approval from regulators. The Challenge Choosing What to Leave Out When the Evidence Runs Deep Over his long career, the client had produced hundreds of documents that could support the petition. The main challenge in this case was deciding which evidence to focus on and which material to leave out. A strong O-1A petition depends on the quality of the evidence, not the quantity. Including too much can make the strongest achievements harder to see. The task, then, was to identify the evidence that demonstrated extraordinary ability most clearly and to present that material in a focused and well-organized way. Strategic Approach Building the Petition Around Five of the Eight O-1A Criteria To qualify for an O-1A visa, a person must meet at least three of eight possible standards that USCIS uses to measure extraordinary ability. Attorney Slomski built the I-129 filing around five of the eight O-1A criteria, drawing on the strongest evidence from across the client’s career. The center of the case was the treatment approach he developed for patients with advanced colorectal cancer who had previously been considered too sick for surgery. This supported the original contribution of major significance criterion. His published research, still cited by other scientists today, showed a long record of respected scholarly work and professional recognition spanning decades. The petition connected his senior positions at leading cancer research organizations to the criterion for critical or essential roles at distinguished organizations. It also documented his work reviewing clinical trial safety and evaluating research for a medical journal, which supported the criterion for judging the work of others. The petition also showed that he earns a high salary for his field. Rather than compare his pay to United States figures, the legal team used wage data for the region where he worked to show that he earned well above others in the same role. See If You QualifyGet your free O-1 visa evaluation today. Evaluate My Profile The Result O-1A Approved Without an RFE USCIS approved the client’s O-1A petition without issuing an RFE, meaning USCIS approved it on the first submission without asking for additional documentation. This approval allows the client to continue his work in the United States, guiding the development of new cancer treatments and helping bring them to the patients who need them. Case Overview Category Details Visa Classification O-1A (Extraordinary Ability) Country of Origin Russia Professional Field Oncology and cancer drug development Education Medical Degree (MD) and PhD in Medicine Request for Evidence (RFE) No Outcome Approved Attorney Senior Immigration Attorney Rachel Slomski Date of Approval June 16, 2026 Attorney Perspective Rachel SlomskiSenior AttorneyRead More “This case is a good reminder that more criteria is not always better. Our client had decades of work and could have qualified under several more criteria, but the stronger strategy was to focus on his best evidence and leave out anything that could invite questions. That focus is what made the petition airtight.” EB-2 NIW Green Card Case Study: Approval for Financial Researcher from Brazil E-2 Visa Case Study: Swedish Investor Approved After Purchasing a Florida Hair Salon EB-2 NIW Green Card Case Study: Approval for Marketing Strategist from El Salvador EB-2 NIW Green Card Case Study: Approval for Wildlife Conservation Scientist from Mexico O-1A Case Study: Visa Approval for Aerospace Engineer & Startup Founder from Taiwan EB-2 NIW Green Card Case Study: Approval for Aerospace Engineer from Argentina EB-2 NIW Case Study: Civil Engineer from Venezuela Approved in Two Months Without RFE EB-2 NIW Case Study: Approval for an Agricultural Engineer from Colombia This case was led by Senior Immigration Attorney Rachel Slomski of Colombo & Hurd, a U.S. immigration law firm specializing in employment-based visas including EB-2 NIW and EB-1A petitions. The firm has secured more than 2,500 approvals in EB-2 NIW and EB-1A categories since 2023.